Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Gene Therapy Adverse Event Tracking System Will Have Broad Scope

Executive Summary

FDA's Gene Therapy Patient Tracking System will attempt to track the full range of adverse events in patients enrolled in gene transfer studies

You may also be interested in...

CBER Gene Therapy Office To Be Established By Oct. 1

CBER's Office of Cells, Tissues & Gene Therapy will address the "evolution" of scientific and regulatory issues, FDA Center for Biologics Evaluation & Research Director Kathryn Zoon, PhD, said May 29

Gene Therapy 15-Year Follow-Up In Four AE Categories Suggested By Cmte.

Gene therapy clinical trial subjects should be followed in four adverse event categories for 15 years, FDA's Biological Response Modifiers Advisory Committee recommended Oct. 24.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts